The case for & against
Bull & Bear analysis
Bearish
Myriad Genetics, Inc. (NASDAQ: MYGN) is a leading player in the genetic testing sector, specializing in hereditary cancer testing, oncology, prenatal health, and mental health diagnostics. The company is at the forefront of the precision medicine movement, emphasizing the importance of genetic insights to enhance patient care through innovative testing solutions. Myriad is focusing on its cancer care continuum strategy, addressing hereditary cancer risks, and maintaining a competitive edge through strategic product launches and enhancements in operational efficiency.
Bull says
- ↑MyRisk hereditary cancer tests rose 10% YoY, boosting test volumes.
- ↑Launched AI-enabled Prolaris prostate cancer assay, with positive early feedback.
- ↑ASCEND efficiency program targets adjusted EBITDA gains from 2027 onward.
- ↑Q2 cash reserves of $190M and Book-to-Price ratio 2.27 imply undervaluation.
- ↑First Gene combined prenatal/carrier screening launch could regain prenatal share.
- ↑Low leverage and strong liquidity support operational investments and risk resilience.
Bear says
- ↓Q2 revenue declined 11% YoY to $190.7M; 2026 guidance lowered to $770–790M.
- ↓Average revenue per test fell 9% YoY amid payer-driven reimbursement friction.
- ↓Negative profitability outlook undermines margins and investor confidence.
- ↓High short interest and volatility signal market skepticism and price swings.
- ↓Prenatal segment inefficiencies and intensifying competition threaten future growth.
- ↓Negative momentum and elevated volatility factors increase investment risk.
Investment themes with MYGN
Biotech↓ -1.57%
Genetic and drug innovations driving medical breakthroughs
APLS · RVMD · SMMT
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-04-2026neutral
Transcript signals
Bull points
- we are happy that we've been able to, through the actions we've deliberately taken, increase the growth of GeneSight back to where we expected it to be by year-end, which is mid-single digits.
- we plan on submitting three publications as part of United's typical review cycle, which takes place in the fall. Two have already been published, both in the Journal of Clinical Psychopharmacology. One was an economic utility study that we did with Optum. The other one is a new meta-analysis focusing on the randomized trials related to gene site.
- you know, by year end, we expect to have more clinical, you know, utility work that's done and to submit for Moldex by sometime in Q1, expecting Moldex, if they're with customary timelines, approval sometime towards the end of the year.
Bear points
- we're likely not going to launch a precise liquid product that is, you know, based on the assets, if you will, that we acquired last year.
- hereditary cancer testing journey was flagged as one of the headwind items, illustrating challenges to meeting expectations for volume growth.
- prenatal challenges that we're kind of newly referencing now, we certainly expect to significantly rectify in the second half of the year.
Read full transcript analysis ›